Evolution in women's cancer diagnostics: from histopathology to molecular testing, personalized treatment for breast, ovarian ...

Ernexa Therapeutics embarks on new strategic direction, shifting the company’s focus from delivering a cell therapy platform to prioritizing ...

Dr Kathleen Moore from the University of Oklahoma Health Sciences Center reviews key ovarian cancer abstracts from ESGO 2025. She first highlights a multicenter study comparing three vs six cycles ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

A new study has identified the protein ADAMTS5 as playing a crucial role in the spread of ovarian cancer cells, offering a ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, ...

Black and American Indian patients are less likely to have elevated CA-125 levels compared with White patients.

University of Kentucky Markey Cancer Center researchers presented promising results from an early-stage clinical trial ...

“Eterna Therapeutics began as a pioneer developing an innovative and differentiated cell therapy platform alone, but today, we have entered a new era of evolution and growth,” said Sanjeev ...

CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics, a leader in cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the company’s ...